human IL-22 / Synlogic - LARVOL DELTA

ENGINEERING SYNTHETIC BIOTIC MEDICINES TO SECRETE HUMAN PROTEINS AND SHORT CHAIN FATTY ACIDS AS A VERSATILE PLATFORM TO TREAT INFLAMMATORY BOWEL DISEASE (DDW 2022) - "We further show that the EcN-IL22 strain secretes high levels of human IL22 in mice as measured by hIL22 recovery in feces and colon tissue, and increases colonic gene expression of reg3B and birc5 mRNA indicating in vivo target engagement. Finally, the engineering of molecular tools, including a GFP reporter system, demonstrates the ability of EcN to respond to various environmental and chemical inputs, utilizing either natural or synthetic promoters as biosensors, including a biosensor responsive to reactive nitrogen species characteristic of an inflamed gut.Taken together, these data show disparate modalities engineered into EcN can influence inflammatory pathways and provide a framework towards developing therapeutics targeting inflammation based pathologies in the gut, including IBD."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immune Modulation • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • BIRC5 • IL22

[VIRTUAL] A NOVEL HUMAN IL-22-SECRETING SYNTHETIC BIOTIC MEDICINE FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (DDW 2021) - "Our data demonstrate that an engineered EcN results in significant secretion of bioactive human IL-22 leading to target engagement in mice. Overall, these results suggest that bacterial engineering is a viable approach to generate localized delivery of immunological payloads to the gut and support the development of Synthetic Biotic Medicines as a novel approach to treat intestinal immune-mediated diseases."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • BIRC5 • IL22 • STAT3

Synlogic announces termination of AbbVie collaboration agreement (PRNewswire) - "Synlogic, Inc....today announced the termination of its collaboration with AbbVie...for the development of Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD)....Upon termination, Synlogic regains all rights to develop these and new IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows Synlogic to fully leverage its expertise in strain engineering, quantitative biology, regulatory, and manufacturing of living medicines to expand its wholly owned GI-based program portfolio to include IBD. Synlogic further regains the rights to partner its IBD programs."

Licensing / partnership • Inflammatory Bowel Disease